Skip to main content
Premium Trial:

Request an Annual Quote

Interleukin Genetics' Q2 Revenues Rise 33 Percent

NEW YORK (GenomeWeb News) – Interleukin Genetics today reported that its second-quarter revenues rose 33 percent on higher genetic test sales.

The Waltham, Mass.-based firm brought in total revenues of $800,000 for the three months ended June 30, compared to $600,000 for the second quarter of 2010. Almost all of its revenues were from genetic test sales.

Interleukin Genetics CEO Lewis Bender said that the revenue growth was "primarily driven by partnerships for our Weight Management Genetic Test."

The firm's net loss declined to $1.2 million, or $.03 per share, from $1.4 million, or $.04 per share, for Q2 2010.

Its R&D spending climbed around 11 percent to $359,799 from $325,298, while its SG&A expenses fell 19 percent to $1.3 million from $1.6 million. Interleukin said the drop was due to "lower compensation, professional fees, and promotion expenses partially offset by increased patent-related legal fees and sales commissions paid to Amway."

Interleukin Genetics finished the quarter with $1.7 million in cash and cash equivalents.

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.